Organisation paid for research Program year 2025 Source: CMS Open Payments

HMD Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,419,047

381 payments

Through program year 2025, HMD Research LLC is reported as receiving $1,419,047 in research payments, across 381 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$292,521	60
2024	Research	$265,048	51
2023	Research	$174,045	70
2022	Research	$142,852	64
2021	Research	$88,956	29
2020	Research	$136,169	47
2019	Research	$319,457	60

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $894,835 250 payments
Sanofi US Services Inc. $138,298 14 payments
Romark Laboratories, LC $95,649 1 payment
Genzyme Corporation $78,652 27 payments
Hikma Pharmaceuticals USA $64,274 9 payments
Pfizer Inc. $45,163 27 payments
Teva Pharmaceuticals USA, Inc. $24,310 8 payments
Genentech, Inc. $17,510 5 payments
Takeda Pharmaceuticals U.S.A., Inc. $15,500 2 payments
Celgene Corporation $14,802 2 payments

Studies the money was for Research payments · program years 2019–2025

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $234,678 26 payments
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies $108,838 13 payments
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection $95,649 1 payment
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 $88,802 26 payments
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma $78,652 27 payments
M16-063 $77,859 18 payments
M15-998 $73,386 19 payments
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) $60,744 23 payments
M16-011 $43,691 13 payments
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $41,586 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.